title: Invasive aspergillosis in 2002: an update.
abstract: Despite significant advances in the management of immunosuppressed patients, invasive aspergillosis remains an important life-threatening complication. In the past two decades, the incidence of invasive aspergillosis in this population has continued to increase. Factors that predispose patients to develop invasive aspergillosis include prolonged granulocytopenia, the development of graft-versus-host disease, immunosuppressive therapy, the use of adrenal corticosteroids, and the prolonged impairment of host defenses associated with diseases such as chronic granulomatous disease. Environmental factors also play a key part in the pathogenesis of this infection, and therefore, infection control measures play a critical role in reducing exposure of patients to Aspergillus. New exciting developments in the early diagnosis of invasive aspergillosis and the acceleration of antifungal drug discovery offer promise for the future.
authors.affiliation: Department of Infectious Diseases, Infection Control and Employee Health, Box 402, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. dkontoyi@mdanderson.org
authors.forename: D P
authors.initials: DP
authors.lastname: Kontoyiannis
authors.forename: G P
authors.initials: GP
authors.lastname: Bodey
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D003428:Cross Infection; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D017053:Infection Control
chemical_list: D000935:Antifungal Agents